Bellerophon Therapeutics Inc
F:6L7A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (21.8), the stock would be worth €-21.8 (6 329% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | €0.35 |
0%
|
| Industry Average | 21.8 | €-21.8 |
-6 329%
|
| Country Average | 21.9 | €-21.85 |
-6 343%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
B
|
Bellerophon Therapeutics Inc
F:6L7A
|
3.7m EUR | -0.4 | -0.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.6B USD | 65.3 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
155.4B USD | 29 | 24.8 | |
| US |
|
Stryker Corp
NYSE:SYK
|
112.7B USD | 20.7 | 34.7 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
102.7B USD | 27.3 | 22.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
83.8B USD | 29.3 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.8B USD | 37 | 44.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.2B USD | 46 | 42.7 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.5B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
29.9B USD | 17.2 | 20.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Bellerophon Therapeutics Inc
Glance View
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.
